의약품 분석 검사 아웃소싱 시장 규모, 점유율, 동향 분석 리포트 : 서비스별, 최종 용도별, 지역별, 부문 예측(2025-2030년)

Pharmaceutical Analytical Testing Outsourcing Market Growth & Trends:

The global pharmaceutical analytical testing outsourcing market size is estimated to reach USD 14.56 billion by 2030 and is projected to grow at a CAGR of 8.6% from 2025 to 2030. Increasing biological candidate pipelines, rising demand for additional analytical details on drugs, and process development by regulatory agencies are driving market growth. Analytical testing aids in real-time product quality control as well as help optimize and monitor processes, thereby identifying different drugs. Over the years, the number of clinical trials has increased consistently.

For instance, in 2021, over 399,525 clinical studies were registered on ClinicalTrial.gov, whereas as of June 2022, it had increased to over 421,258 studies. A continuation of this trend is expected to have a positive impact on the market in the post-pandemic period. The majority of small and medium-sized pharma companies lack the infrastructure for analytical testing. As a result, outsourcing these operations is the best option as it saves time and money. The patent cliff, primarily for small molecules and biologics, is likely to have a positive impact on the market as it will increase the number of commercial drugs in the pharma market, thus promoting the analytical testing of commercially available generic drugs.

There has been a rise in several diseases post-COVID-19. For instance, according to a report published by Children's National Hospital- pediatric research and clinical innovations center, a study was performed on 737 youths who were diagnosed with diabetes, and it found an increased incidence of pediatric Type 1 Diabetes (T1D) by 15.2% and Type 2 Diabetes (T2D) increased by 182% between March 11, 2018, and March 10, 2021. The rise in disease incidence is expected to improve, drug production, which is likely to drive the demand for analytical services for commercial drugs .

Pharmaceutical Analytical Testing Outsourcing Market Report Highlights:

• The bioanalytical testing segment dominated the market, accounting for a revenue share of 38.44% in 2024. Bioanalytical testing covers both clinical and non-clinical studies.
• The pharmaceutical segment gained the largest market share in 2024. The growing demand among pharmaceutical companies to focus on their core competencies is one of the major reasons for the largest segment share.
• North America is expected to hold the largest revenue share of 52.91% owing to the presence of a significant number of pharmaceutical companies in the region.
• Asia Pacific is anticipated to be the fastest-growing regional market from 2025 to 2030 due to the low-cost service offerings by third-party service providers in the region.

Table of Contents

Chapter 1. Research Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Service
  • 1.2.2. End Use
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information Or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity Flow Analysis
  • 1.7.2. Parent Market Analysis
• 1.8. List Of Secondary Sources
• 1.9. List Of Abbreviations
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Pharmaceutical Analytical Testing Outsourcing Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Clinical Trials Volume Analysis, (2024)
  • 3.3.1. Total Number Of Clinical Trials By Region
  • 3.3.2. Total Number Of Clinical Trials, By Phase
  • 3.3.3. Total Number Of Clinical Trials, By Study Design
  • 3.3.4. Total Number Of Clinical Trials, By Key Therapeutic Area
• 3.4. Pricing Model Analysis
• 3.5. Technology Landscape
• 3.6. Market Analysis Tools
  • 3.6.1. Porter's Five Force Analysis
  • 3.6.2. PESTEL by SWOT Analysis
  • 3.6.3. COVID-19 Impact Analysis

Chapter 4. Pharmaceutical Analytical Testing Outsourcing Market: Service Estimates & Trend Analysis

• 4.1. Pharmaceutical Analytical Testing Outsourcing Market, By Service: Segment Dashboard
• 4.2. Pharmaceutical Analytical Testing Outsourcing Market, By Service: Movement Analysis
• 4.3. Pharmaceutical Analytical Testing Outsourcing Market Estimates & Forecasts, By Service, 2018 - 2030 (USD Million)
• 4.4. Bioanalytical Testing
  • 4.4.1. Bioanalytical Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4.2. Clinical
    • 4.4.2.1. Clinical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4.3. Non-Clinical
    • 4.4.3.1. Non-Clinical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.5. Method Development & Validation
  • 4.5.1. Method Development & Validation Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5.2. Extractable & Leachable
    • 4.5.2.1. Extractable & Leachable Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5.3. Impurity Method
    • 4.5.3.1. Impurity Method Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5.4. Technical Consulting
    • 4.5.4.1. Technical Consulting Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5.5. Others
    • 4.5.5.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.6. Stability Testing
  • 4.6.1. Stability Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6.2. Drug Substance
    • 4.6.2.1. Drug Substance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6.3. Stability Indicating Method Validation
    • 4.6.3.1. Stability Indicating Method Validation Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6.4. Accelerated Stability Testing
    • 4.6.4.1. Accelerated Stability Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6.5. Photostability Testing
    • 4.6.5.1. Photostability Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6.6. Others
    • 4.6.6.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.7. Others
  • 4.7.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Pharmaceutical Analytical Testing Outsourcing Market: End Use Estimates & Trend Analysis

• 5.1. Pharmaceutical Analytical Testing Outsourcing Market, By End Use: Segment Dashboard
• 5.2. Pharmaceutical Analytical Testing Outsourcing Market, By End Use: Movement Analysis
• 5.3. Pharmaceutical Analytical Testing Outsourcing Market Estimates & Forecasts, By End Use, 2018 - 2030 (USD Million)
• 5.4. Pharmaceutical Companies
  • 5.4.1. Pharmaceutical Companies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.5. Biopharmaceutical Companies
  • 5.5.1. Biopharmaceutical Companies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.6. Contract Research Organizations
  • 5.6.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Pharmaceutical Analytical Testing Outsourcing Market: Regional Estimates & Trend Analysis

• 6.1. Regional Market Dashboard
• 6.2. Regional Market Share Analysis, 2024 & 2030
• 6.3. North America
  • 6.3.1. North America Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.3.2. U.S
    • 6.3.2.1. Key Country Dynamics
    • 6.3.2.2. Competitive Scenario
    • 6.3.2.3. Regulatory Framework
    • 6.3.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.3.3. Canada
    • 6.3.3.1. Key Country Dynamics
    • 6.3.3.2. Competitive Scenario
    • 6.3.3.3. Regulatory Framework
    • 6.3.3.4. Canada Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.3.4. Mexico
    • 6.3.4.1. Key Country Dynamics
    • 6.3.4.2. Competitive Scenario
    • 6.3.4.3. Regulatory Framework
    • 6.3.4.4. Mexico Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.4. Europe
  • 6.4.1. Europe Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.2. UK
    • 6.4.2.1. Key Country Dynamics
    • 6.4.2.2. Competitive Scenario
    • 6.4.2.3. Regulatory Framework
    • 6.4.2.4. UK Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.3. Germany
    • 6.4.3.1. Key Country Dynamics
    • 6.4.3.2. Competitive Scenario
    • 6.4.3.3. Regulatory Framework
    • 6.4.3.4. Germany Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.4. France
    • 6.4.4.1. Key Country Dynamics
    • 6.4.4.2. Competitive Scenario
    • 6.4.4.3. Regulatory Framework
    • 6.4.4.4. France Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.5. Italy
    • 6.4.5.1. Key Country Dynamics
    • 6.4.5.2. Competitive Scenario
    • 6.4.5.3. Regulatory Framework
    • 6.4.5.4. Italy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.6. Spain
    • 6.4.6.1. Key Country Dynamics
    • 6.4.6.2. Competitive Scenario
    • 6.4.6.3. Regulatory Framework
    • 6.4.6.4. Spain Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.7. Sweden
    • 6.4.7.1. Key Country Dynamics
    • 6.4.7.2. Competitive Scenario
    • 6.4.7.3. Regulatory Framework
    • 6.4.7.4. Sweden Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.8. Denmark
    • 6.4.8.1. Key Country Dynamics
    • 6.4.8.2. Competitive Scenario
    • 6.4.8.3. Regulatory Framework
    • 6.4.8.4. Denmark Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.9. Norway
    • 6.4.9.1. Key Country Dynamics
    • 6.4.9.2. Competitive Scenario
    • 6.4.9.3. Regulatory Framework
    • 6.4.9.4. Norway Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.5. Asia Pacific
  • 6.5.1. Asia Pacific Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.2. Japan
    • 6.5.2.1. Key Country Dynamics
    • 6.5.2.2. Competitive Scenario
    • 6.5.2.3. Regulatory Framework
    • 6.5.2.4. Japan Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.3. China
    • 6.5.3.1. Key Country Dynamics
    • 6.5.3.2. Competitive Scenario
    • 6.5.3.3. Regulatory Framework
    • 6.5.3.4. China Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.4. India
    • 6.5.4.1. Key Country Dynamics
    • 6.5.4.2. Competitive Scenario
    • 6.5.4.3. Regulatory Framework
    • 6.5.4.4. India Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.5. Thailand
    • 6.5.5.1. Key Country Dynamics
    • 6.5.5.2. Competitive Scenario
    • 6.5.5.3. Regulatory Framework
    • 6.5.5.4. Thailand Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.6. South Korea
    • 6.5.6.1. Key Country Dynamics
    • 6.5.6.2. Competitive Scenario
    • 6.5.6.3. Regulatory Framework
    • 6.5.6.4. South Korea Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.7. Australia
    • 6.5.7.1. Key Country Dynamics
    • 6.5.7.2. Competitive Scenario
    • 6.5.7.3. Regulatory Framework
    • 6.5.7.4. Australia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.6. Latin America
  • 6.6.1. Latin America Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.2. Brazil
    • 6.6.2.1. Key Country Dynamics
    • 6.6.2.2. Competitive Scenario
    • 6.6.2.3. Regulatory Framework
    • 6.6.2.4. Brazil Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.3. Argentina
    • 6.6.3.1. Key Country Dynamics
    • 6.6.3.2. Competitive Scenario
    • 6.6.3.3. Regulatory Framework
    • 6.6.3.4. Argentina Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.7. MEA
  • 6.7.1. MEA Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7.2. South Africa
    • 6.7.2.1. Key Country Dynamics
    • 6.7.2.2. Competitive Scenario
    • 6.7.2.3. Regulatory Framework
    • 6.7.2.4. South Africa Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7.3. Saudi Arabia
    • 6.7.3.1. Key Country Dynamics
    • 6.7.3.2. Competitive Scenario
    • 6.7.3.3. Regulatory Framework
    • 6.7.3.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7.4. UAE
    • 6.7.4.1. Key Country Dynamics
    • 6.7.4.2. Competitive Scenario
    • 6.7.4.3. Regulatory Framework
    • 6.7.4.4. UAE Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7.5. Kuwait
    • 6.7.5.1. Key Country Dynamics
    • 6.7.5.2. Competitive Scenario
    • 6.7.5.3. Regulatory Framework
    • 6.7.5.4. Kuwait Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Market Participant Categorization
• 7.2. Company Market Share/Assessment Analysis, 2024
• 7.3. Company Profiles
  • 7.3.1. SGS Societe Generale de Surveillance SA
    • 7.3.1.1. Company Overview
    • 7.3.1.2. Financial Performance
    • 7.3.1.3. Service Benchmarking
    • 7.3.1.4. Strategic Initiatives
  • 7.3.2. Labcorp
    • 7.3.2.1. Company Overview
    • 7.3.2.2. Financial Performance
    • 7.3.2.3. Service Benchmarking
    • 7.3.2.4. Strategic Initiatives
  • 7.3.3. Eurofins Scientific
    • 7.3.3.1. Company Overview
    • 7.3.3.2. Financial Performance
    • 7.3.3.3. Service Benchmarking
    • 7.3.3.4. Strategic Initiatives
  • 7.3.4. Pace Analytical Services LLC
    • 7.3.4.1. Company Overview
    • 7.3.4.2. Financial Performance
    • 7.3.4.3. Service Benchmarking
    • 7.3.4.4. Strategic Initiatives
  • 7.3.5. Intertek Group plc
    • 7.3.5.1. Company Overview
    • 7.3.5.2. Financial Performance
    • 7.3.5.3. Service Benchmarking
    • 7.3.5.4. Strategic Initiatives
  • 7.3.6. PPD Inc (Thermo Fisher Scientific Inc.)
    • 7.3.6.1. Company Overview
    • 7.3.6.2. Financial Performance
    • 7.3.6.3. Service Benchmarking
    • 7.3.6.4. Strategic Initiatives
  • 7.3.7. Wuxi AppTec
    • 7.3.7.1. Company Overview
    • 7.3.7.2. Financial Performance
    • 7.3.7.3. Service Benchmarking
    • 7.3.7.4. Strategic Initiatives
  • 7.3.8. BA Sciences
    • 7.3.8.1. Company Overview
    • 7.3.8.2. Financial Performance
    • 7.3.8.3. Service Benchmarking
    • 7.3.8.4. Strategic Initiatives
  • 7.3.9. Charles River Laboratories
    • 7.3.9.1. Company Overview
    • 7.3.9.2. Financial Performance
    • 7.3.9.3. Service Benchmarking
    • 7.3.9.4. Strategic Initiatives
  • 7.3.10. West Pharmaceutical Services, Inc
    • 7.3.10.1. Company Overview
    • 7.3.10.2. Financial Performance
    • 7.3.10.3. Service Benchmarking
    • 7.3.10.4. Strategic Initiatives